Migraine market
Aug 12, 2025
Teva’s AJOVY Expanded by FDA as First Anti-CGRP Preventive for Pediatric Episodic Migraine; NRx Pharma’s NRX-100 Granted FDA Fast Track for Suicidal Ideation in Depression/Bipolar Depression; Boehringer Ingelheim’s HERNEXEOS Wins FDA Accelerated Approval for HER2-Mutant Advanced NSCLC; Genmab’s Phase III EPCORE FL-1 Meets Dual Endpoints in Relapsed/Refractory Follicular Lymphoma; Tiziana’s Phase II IND Cleared by FDA for Multiple System Atrophy
FDA Expands Teva’s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6–...
Read More...
Nov 29, 2021
Neuromodulation Devices Observed to Reshape the Migraine Treatment Dynamics
Migraine is the most commonly encountered disabling disorder that can be featured as attacks of severe, unilateral, and a pulsating form of headache composed of symptoms such as photophobia, phonophobia, nausea, vomiting, and cutaneous allodynia. As per the Migraine Research Foundation 2021, Migraine is considered ...
Read More...
Jun 09, 2021
Migraine Market: How Pharma Companies are trying to Uncomplicate the Disease and Bring in Novel Therapies
Migraine is a medical condition characterized by recurrent headaches that can last from 4 to 72 hours and often results in a wide range of symptoms. It is mainly associated with a painful headache, however, the affected person may experience nausea, vomiting, disturbed vision, sensitivity to light, sound, and smell...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
